TRVN Trevena Inc.

0.97
-0.01  -1%
Previous Close 0.97
Open 0.99
Price To Book 2.62
Market Cap 89,630,255
Shares 92,593,239
Volume 796,209
Short Ratio
Av. Daily Volume 613,238
Stock charts supplied by TradingView

NewsSee all news

  1. Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder

    CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system

  2. Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting

    Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company

  3. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  4. Trevena Announces Publication of Results from Special Population Studies for Oliceridine

    No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a

  5. Trevena Announces Publication of Results from Phase 3 "Real World" Safety Study for Oliceridine in The Journal of Pain Research

    Safety and tolerability demonstrated in diverse patient populations and surgeries CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued November 2, 2018. NDA to be resubmitted 1Q 2020.
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 2b endpoints not met - May 2016
TRV027 - BLAST-AHF
Acute heart failure
Phase 1 data due 2H 2020.
TRV250
Acute migraine
Proof of concept trial initiation announced December 23, 2019.
TRV734
Opioid use disorder

Latest News

  1. Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder

    CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system

  2. Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting

    Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company

  3. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  4. Trevena Announces Publication of Results from Special Population Studies for Oliceridine

    No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a

  5. Trevena Announces Publication of Results from Phase 3 "Real World" Safety Study for Oliceridine in The Journal of Pain Research

    Safety and tolerability demonstrated in diverse patient populations and surgeries CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the

  6. Trevena to Present at the Stifel 2019 Healthcare Conference

    CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system

  7. Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study

    Company expects to resubmit NDA for oliceridine in Q1 2020  Acute migraine proof-of-concept study for TRV250 initiated  Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04, 2019 (GLOBE

  8. Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting

    CHESTERBROOK, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system

  9. Trevena to Present at the 2019 Cantor Global Healthcare Conference

    CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous

  10. Trevena to Participate in Upcoming Conferences in September 2019

    CHESTERBROOK, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous

  11. TREVENA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Trevena, Inc. - TRVN

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Trevena, Inc. (NASDAQ:TRVN). On

  12. Trevena Advances NDA Resubmission Activities for Oliceridine

    — Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — CHESTERBROOK, Pa., Aug.